- Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
- Evaluating over 40 MTAP PDX preclinical models, squamous NSCLC was identified as the most sensitive tumor type to IDE397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg QD
- Over 100,000 global annual incidence of MTAP-deletion squamous NSCLC
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.